Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

29 Mar 2010

Abstract excerpt

BACKGROUND: Clonal evolution is frequently detected in patients developing resistance to imatinib. The outcome of patients with clonal evolution treated with second generation tyrosine kinase inhibitors is not known. METHODS: The authors analyzed the outcome of 177 CML patients after second tyrosine kinase inhibitor therapy. RESULTS: Ninety-five patients were in chronic phase, 30 had clonal evolution, 28 were in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20499401
DOI: 10.1002/cncr.25015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapyPMID 20499401Read ↗

Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.Semantic proximity Read ↗

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapySemantic proximity Read ↗

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CMLSemantic proximity Read ↗

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapySemantic proximity Read ↗

Clonal dominance and clonal evolution in a patient with a "chronic myeloid neoplasm": a challenge in management.Semantic proximity Read ↗

Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Clonal evolution in chronic myelogenous leukemiaSemantic proximity Read ↗

Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival.Semantic proximity Read ↗

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.Semantic proximity Read ↗

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemiaSemantic proximity Read ↗

High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature.Semantic proximity Read ↗

Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.